Enoxaparin and abciximab adjunctive pharmacotherapy during Percutaneous Coronary Intervention

Journal of Invasive Cardiology

Volumn 13, Issue 4, 2001, Pages 272-278

  Kereiakes, Dean J ^a   Grines, Cindy ^b   Fry, Edward ^c   Esente, Paola ^d   Hoppensteadt, Debra ^e   Midei, Mark ^f   Barr, Lawrence ^g   Matthai, William ^h   Todd, Mark ⁱ   Broderick, Thomas ^a   Rubinstein, Ronald ^j   Fareed, Jawad ^e   Santoian, Edward ^k   Neiderman, Alan ^l   Brodie, Bruce ^m   Zidar, James ⁿ   Ferguson, James J ^o   Cohen, Marc ^p  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ST JOSEPH S HOSPITAL HEALTH CENTER   (United States)

^e LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^f Midatlantic Cardiovascular Associates   (United States)

^g Midwest Heart Research Foundation   (United States)

^h PENN PRESBYTERIAN MEDICAL CENTER   (United States)

ⁱ Aventis Pharmaceuticals   (United States)

^j Premier Cardiology Research   (United States)

^k Orlando Heart Center   (United States)

^l Greater Ft Lauderdale Heart Group Research   (United States)

^m LeBauer Cardiovascular Research Foundation   (United States)

ⁿ DUKE UNIVERSITY MEDICAL CENTER   (United States)

^o TEXAS HEART INSTITUTE   (United States)

^p HAHNEMANN UNIVERSITY HOSPITAL   (United States)

more..

Author keywords

Anticoagulation; Coronary angioplasty; Enoxaparin

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; ENOXAPARIN; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG COMBINATION; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CORONARY DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENOXAPARIN; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 0035318112     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Laskey MAL, Deutsch E, Barnathan E, Laskey WK. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in unstable angina pectoris. Am J Cardiol 1990;65:1425-1429.
2. Pow TK, Varrichione TR, Jacobs AK, et al. Does pretreatment with heparin prevent abrupt closure following PTCA? (Abstr). J Am Coll Cardiol 1988;11:238A.
3. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA 1996;276:811-815.
4. Braunwald E, Mark DB, Jones RH, et al. Unstable Angina: Diagnosis and Management. Agency for health care policy and research and the National Heart, Lung and Blood Institute, Public Health Service. Rockville, MD. 1994: pp. 6-12.
5. Ferguson JJ, Dougherty KG, Gaos CM, et al. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:1061-1065.
6. Narins CR, Hillegass WB, Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:667-671.
7. Hillegas WB, Narins CR, Brott BC, et al. Activated clotting time predicts bleeding complications from angioplasty (Abstr). J Am Coll Cardiol 1994;23:184A.
8. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-452.
9. Antman EM, McCabe CH, Gurfinkel P, et al. for the TIMI IIB Investigators. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction - Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B Trial. Circulation 1999;100:1593-1601.
10. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994;330:956-961.
11. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
12. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
13. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-1428.
14. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998;98:2829-2835.
15. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
16. Waters D, Azar RR. Low molecular weight heparins for unstable angina: A better mousetrap? Circulation 1997;96:3-5.
17. Turpie AGG. Successors to heparin: New antithrombotic agents. Am Heart J 1997;134:S71-S77.
18. Antman EM, Handin R. Low-molecular-weight heparins. An intriguing new twist with profound implications. Circulation 1998;98:287-289.
19. Rabah MM, Premmereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999;84:1391-1395.